Optimal Adjuvant Endocrine Therapy for Early Breast Cancer
Adjuvant endocrine therapy substantially reduces tumor recurrence and mortality in pre- and post-menopausal women with hormone receptor-positive early breast cancer but is ineffective in women with hormone receptor-negative tumors. Tamoxifen has been the
|Collections||ANU Research Publications|
|01_Stuart-Harris_Optimal_Adjuvant_Endocrine_2010.pdf||540.27 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.